Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024

July 26, 2024

https://www.globenewswire.com/news-release/2024/07/26/2919863/0/en/Cognition-Therapeutics-to-Host-Investor-Webcast-to-Discuss-Results-from-Proof-of-Concept-Phase-2-SHINE-Study-of-CT1812-in-Mild-to-Moderate-Alzheimer-s-Disease-at-8-30am-ET-on-Monda.html

PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024 at 8:30a.m. ET to discuss the clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” study. SHINE enrolled 153 adults with mild-to-moderate Alzheimer’s disease who were randomized to receive once-daily oral doses of CT1812 (100mg or 300mg) or placebo for six months. The only way to participate in the live webcast is to register online by clicking here. The event will also be archived on the Investor Relations section of the Cognition website.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.